Search

Simple Summary: This paper proposes a modified SEIR model to study COVID-19 in Wuhan. The modified model is calibrated by the public number of COVID-19 hospitalization cases in Wuhan. The paper further uses this model to estimate the earliest date of COVID-19 infection in Wuhan, which is in agreement with some existing results. Based on SEIR (susceptible–exposed–infectious–removed) epidemic model, we propose a modified epidemic mathematical model to describe the spread of the coronavirus disease 2019 (COVID-19) epidemic in Wuhan, China. Using public data, the uncertainty parameters of the proposed model for COVID-19 in Wuhan were calibrated. The uncertainty of the control basic reproduction number was studied with the posterior probability density function of the uncertainty model parameters. The mathematical model was used to inverse deduce the earliest start date of COVID-19 infection in Wuhan with consideration of the lack of information for the initial conditions of the model. The result of the uncertainty analysis of the model is in line with the observed data for COVID-19 in Wuhan, China. The numerical results show that the modified mathematical model could model the spread of COVID-19 epidemics. [ABSTRACT FROM AUTHOR]

Simple Summary: The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first encountered in December of 2019 in Wuhan, China. As of now, there have been over 200 million infections and 4 million deaths attributed to the virus. Due to this, it has been a priority to find an effective preventative measure, and numerous vaccines have been developed. Although the developed vaccines share the target of blocking viral entry by the spike protein, their pharmacology and efficacy differs. As such, the mechanism of action and the elicited immune response of the most common COVID-19 vaccines have been compared to help determine which vaccine is most efficacious and is best suited to prevent reinfection and address viral mutations. It has been over a year since SARS-CoV-2 was first reported in December of 2019 in Wuhan, China. To curb the spread of the virus, many therapies and cures have been tested and developed, most notably mRNA and DNA vaccines. Federal health agencies (CDC, FDA) have approved emergency usage of these S gene-based vaccines with the intention of minimizing any further loss of lives and infections. It is crucial to assess which vaccines are the most efficacious by examining their effects on the immune system, and by providing considerations for new technological vaccine strategies in the future. This paper provides an overview of the current SARS-CoV-2 vaccines with their mechanisms of action, current technologies utilized in manufacturing of the vaccines, and limitations in this new field with emerging data. Although the most popular COVID-19 vaccines have been proven effective, time will be the main factor in dictating which vaccine will be able to best address mutations and future infection. [ABSTRACT FROM AUTHOR]